Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.
Trump-era tariffs have been all over the news of late, which led us to speak with international trade expert Jason Waite, of Alston & Bird, in late July. Jason had so much to say, we cut the interview into three parts. Check out
Spanning the first two weeks of August 2025, Pharmaceutical Technology® and Biopharm International® conducted a survey on the impacts of Trump-era tariffs and trade policies on the organizations at which you and your peers in the bio/pharmaceutical industry work. Responses reveal that most perceive tariffs as a major influence on their operations and supply chains, with nearly half reporting significant effects and another large segment anticipating moderate impacts. In navigating these challenges, companies are actively adapting their strategies, primarily by increasing investment in trade compliance and diversifying supply bases, to mitigate risks rather than relying on a single approach, such as reshoring.
